139 related articles for article (PubMed ID: 2491980)
1. Naloxone reversal of buprenorphine-induced respiratory depression.
Gal TJ
Clin Pharmacol Ther; 1989 Jan; 45(1):66-71. PubMed ID: 2491980
[TBL] [Abstract][Full Text] [Related]
2. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine.
Sarton E; Teppema L; Dahan A
Adv Exp Med Biol; 2008; 605():486-91. PubMed ID: 18085322
[TBL] [Abstract][Full Text] [Related]
3. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
4. Naloxone reversal of buprenorphine-induced respiratory depression.
van Dorp E; Yassen A; Sarton E; Romberg R; Olofsen E; Teppema L; Danhof M; Dahan A
Anesthesiology; 2006 Jul; 105(1):51-7. PubMed ID: 16809994
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.
Zamani N; Buckley NA; Hassanian-Moghaddam H
Crit Care; 2020 Feb; 24(1):44. PubMed ID: 32033582
[TBL] [Abstract][Full Text] [Related]
6. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
7. Non-analgesic effects of opioids: opioid-induced respiratory depression.
Boom M; Niesters M; Sarton E; Aarts L; Smith TW; Dahan A
Curr Pharm Des; 2012; 18(37):5994-6004. PubMed ID: 22747535
[TBL] [Abstract][Full Text] [Related]
8. [Influence of four opioids on pulmonary oxygenation and naloxone's effects in mechanically ventilated dogs].
Takahashi H; Dohi S; Matsumiya N; Takeshima R; Naito H
Masui; 1989 Jul; 38(7):880-7. PubMed ID: 2614900
[TBL] [Abstract][Full Text] [Related]
9. [Development of continuous monitoring of spontaneous respiration in the postoperative phase. 2. Cutaneous oxygen and carbon dioxide partial pressures following i.v. bolus application of fentanyl, buprenorphine, naloxone and amiphenazole in healthy adult subjects].
Lehmann KA; Huttarsch H; Schroeder B; Zech D
Anaesthesist; 1992 Apr; 41(4):192-8. PubMed ID: 1350432
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.
Heel RC; Brogden RN; Speight TM; Avery GS
Drugs; 1979 Feb; 17(2):81-110. PubMed ID: 378645
[TBL] [Abstract][Full Text] [Related]
11. Influence of naloxone on the postoperative analgesic and respiratory effects of buprenorphine.
Lehmann KA; Reichling U; Wirtz R
Eur J Clin Pharmacol; 1988; 34(4):343-52. PubMed ID: 3402520
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine.
Ohtani M; Kotaki H; Nishitateno K; Sawada Y; Iga T
J Pharmacol Exp Ther; 1997 Apr; 281(1):428-33. PubMed ID: 9103526
[TBL] [Abstract][Full Text] [Related]
13. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression.
Lötsch J; Skarke C; Schneider A; Hummel T; Geisslinger G
Clin Pharmacol Ther; 2005 Sep; 78(3):278-87. PubMed ID: 16153398
[TBL] [Abstract][Full Text] [Related]
14. Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: quantitative antagonism by naloxone.
Shannon HE; Cone EJ; Gorodetzky CW
J Pharmacol Exp Ther; 1984 Jun; 229(3):768-74. PubMed ID: 6547177
[TBL] [Abstract][Full Text] [Related]
15. Degree and duration of reversal by naloxone of effects of morphine in conscious subjects.
Evans JM; Hogg MI; Lunn JN; Rosen M
Br Med J; 1974 Jun; 2(5919):589-91. PubMed ID: 4833964
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
[TBL] [Abstract][Full Text] [Related]
17. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
[TBL] [Abstract][Full Text] [Related]
18. Effects of buprenorphine, methadone and naloxone on acquisition of behavioral chains.
Cleary J; Ho B; Nader M; Thompson T
J Pharmacol Exp Ther; 1988 Nov; 247(2):569-75. PubMed ID: 3183952
[TBL] [Abstract][Full Text] [Related]
19. Failure of nalbuphine to antagonize morphine: a double-blind comparison with naloxone.
Bailey PL; Clark NJ; Pace NL; Isern M; Stanley TH
Anesth Analg; 1986 Jun; 65(6):605-11. PubMed ID: 3085551
[TBL] [Abstract][Full Text] [Related]
20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
